Drugs / HXTC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03212989 | Jun 2017 → Jun 2022 | HIV infectious disease | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HXTC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03212989 ↗ |
| Action | Deplete | “allow T cells to clear infected cells in vitro” PMID 38349333 ↗ Mar 2024 |
| Modality | Cell therapy | “special immune system cells called expanded HIV-specific T Cell (HXTC) Therapy” NCT03212989 ↗ |